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Abstract
Small interfering RNA (siRNA) targeted therapeutics (STT) offers a compelling alternative to
tradition medications for treatment of genetic diseases by providing a means to silence the ex-
pression of specific aberrant proteins, through interference at the expression level. The per-
ceived advantage of siRNA therapy is its ability to target, through synthetic antisense
oligonucleotides, any part of the genome. Although STT provides a high level of specificity, it is
also hindered by poor intracellular uptake, limited blood stability, high degradability and non-
specific immune stimulation. Since serum proteins has been considered as useful vehicles for
targeting tumors, in this study we investigated the effect of incorporation of human serum albu-
min (HSA) in branched polyethylenimine (bPEI)-siRNA polyplexes in their internalization in ep-
ithelial and endothelial cells. We observed that introduction of HSA preserves the capacity of
bPEI to complex with siRNA and protect it against extracellular endonucleases, while affording
significantly improved internalization and silencing efficiency, compared to bPEI-siRNA poly-
plexes in endothelial and metastatic breast cancer epithelial cells. Furthermore, the uptake of
the HSA-bPEI-siRNA ternary polyplexes occurred primarily through a caveolae-mediated en-
docytosis, thus providing evidence for a clear role for HSA in polyplex internalization. These re-
sults provide further impetus to explore the role of serum proteins in delivery of siRNA.
Introduction
Gene therapy is a therapeutic approach that aims to treat otherwise incurable diseases, like
viral infections, hereditary disorders and cancer by replacing defective genes and the function
of aberrant proteins, through gene incorporation in plasmids or viral vectors for nuclear deliv-
ery [1]. Non-viral systems are however widely preferred, in order to reduce cellular toxicity,
risk of casual gene insertion in the genome and mutagenesis. More recently, the discovery of
endogenous mechanisms involved in regulating gene expression, through antisense oligonucle-
otides has opened a new approach for gene therapy, i.e., targeting a specific gene for silencing
in cells. RNA interference (RNAi) is a mechanism triggered in the cell cytoplasm by exogenous
small interfering RNAs (siRNAs) and endogenous microRNAs (miRNAs), causing the block-
ade of protein translation, by specific mRNA sequence matching [1–2]. During embryogenesis
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and development, miRNAs, which are “nearly” matched sequences coded by the cell genome,
are involved in the regulation of the expression of multiple genes. miRNA expression is tightly
regulated in different tissues and the sequences are conserved across species, indicating that
they have a fundamental role in supervising cell functions [3]. The endogenous role of miRNAs
makes their application in gene therapy rather challenging, since multiple genes can be regulat-
ed by a single miRNA and multiple miRNAs can regulate the expression of a specific gene. siR-
NAs, on the contrary are perfectly matched sequences that can be designed to target a specific
mRNA. Their activity in cells was identified as part of an antiviral response, where retroviral
RNA is recognized in the cell cytoplasm by the RNAi mechanism [4]. Particularly important is
the activation of the RNAi silencing complex (RISC) that recognizes and binds double stranded
siRNAs and miRNAs, through a similar mechanism. Argonaute proteins, which reside within
the RISC complex, unwind siRNAs and miRNAs, allowing RISC to selectively bind the anti-
sense strand, using that as a template to recognize the target mRNAs in the cytoplasm. The im-
perfect match of miRNAs leads mostly to translational repression, while siRNA’s perfect match
causes mRNA cleavage and degradation [2–3]. The design of synthetic siRNA sequences of
21–25 bp, is nowadays employed for specific gene knockdown, with increasing number of
RNAi-based drugs in clinical trials [5–6].
The delivery of siRNA presents many challenges specifically with regards to in vivo injection
and intracellular uptake as siRNA sequences are negatively charged and do not spontaneously
cross the cell membrane. Furthermore, major issues to be considered include degradation by
extracellular nucleases, low blood circulation, renal clearance and difficulties in traversing the
endothelial barrier to reach a target tissue [7–2].
The condensation of siRNA with linear or branched cationic polymers is widely employed
as a packaging and delivery strategy, as this ensures protection of the siRNA from degradation
while promoting non-specific endocytosis, and intracellular escape from endosomes [7–8].
Polycations, although commonly used for condensation and in vivo delivery of siRNA, have as-
sociated toxicity, with an inverse relationship between backbone charge density and toxicity
[9]. The first cationic polymer-siRNA formulation, to enter clinical trial in 2008, was based on
cyclodextrin based nanoparticles containing siRNA (CALAA-01) with incorporation of trans-
ferrin (Tf), as a targeting ligand for tumors [6]. Transferrin transports iron in the bloodstream
and malignant cells have an up-regulated expression of the Tf-receptor [10].
Serum proteins have recently been discovered to serve as endogenous targeting ligands and to
play a role in increasing nanoparticle circulation [5–11]. Recently, Kim et al., have reported that
the adsorption of apolipoprotein A-I, a component of the high density lipoprotein (HDL) by li-
posomes during circulation enables liver targeting of siRNA through a specific receptor-mediated
internalization process in hepatocytes [12]. Therefore, identifying other possible endogenous tar-
geting molecules in circulation can provide new insights and opportunities for siRNA delivery.
Albumin, which is the most abundant protein with physiological function of transporting
fatty acids, has been explored extensively for the delivery of therapeutic molecules. Most nota-
ble is the enhanced delivery and efficacy of paclitaxel when delivered as an albumin conjugated
nanoparticle, Abraxane [11]. Additionally, it has been shown that albumin can accumulate in
tumors through the enhanced permeability and retention mechanism and via specific trans-en-
dothelial transport processes, and is therefore promising as a carrier for anti-cancer drugs [13–
14]. Work to date, on using albumin as a carrier for gene delivery, has focused on the covalent
modification of the albumin molecule to synthesize cationized albumin (CA) [15] or on the
complexation of human serum albumin (HSA) with cationic polymers, to enhance DNA com-
plexation and cell transfection. Poly-L-lysine-coated albumin nanoparticles for example, were
shown to increase siRNA complexation and resistance to enzymatic degradation [16]. Further-
more, some earlier studies have reported the use of polyethylenimine (PEI)-HSA-DNA
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nanocomplexes for gene delivery in cells [17–18]. Abbasi et al., have recently reported the de-
livery of siRNA by complexation with polyethylenimine (PEI)-coated human serum albumin
(HSA) nanoparticles [19]. Son et al., have introduced the concept of using HSA to guide siRNA
delivery to tumors, through nanocarriers formed by disulfide-crosslinking between thiolated
HSA and polymerized siRNA, and have reported increased in vivo accumulation of the nano-
carriers at the tumor sites [20].
Encouraged by these findings, in this study, we explored the role of native unmodified HSA
in mediating the delivery of siRNA in endothelial and breast cancer metastatic cells. Branched
polyethylenimine (bPEI), the most commonly used cationic polymer for nucleic acids delivery,
was complexed with siRNA and HSA was added subsequently for electrostatic incorporation
via bPEI [21–22]. HSA-bPEI-siRNA ternary complexes significantly improved internalization
and silencing efficiency, compared to bPEI-siRNA polyplexes. The presence of free albumin in-
terfered with both internalization and silencing, suggesting an important role for HSA in medi-
ating transfection. The participation of HSA in intracellular trafficking was further elucidated
by uptake mechanism studies.
Materials and Methods
Materials
TurboGFP Stealth RNAi siRNA sequence was designed to target TurboGFP mRNA, with the
on-line program BLOCK-iT RNAi Designer (http://rnaidesigner.lifetechnologies.com/). Tur-
boGFP Stealth RNAi siRNA was used for the characterization studies of the complexes and the
silencing experiments. Sense sequence (5’-3’): GAUAACGAUCUGGAUGGCAGCUUCA, anti-
sense sequence (5’-3’): UGAAGCUGCCAUCCAGAUCGUUAUC.
BLOCK-iT AlexaFluor 555 control siRNA (Invitrogen, Germany) was used for all the up-
take and mechanism studies. Branched polyethylenimine (MW 25 kDa) and Human serum al-
bumin were purchased from Sigma-Aldrich (Germany). Lipofectamine2000 was purchased
from Invitrogen (Germany).
Cell culture
Human primary pulmonary microvascular endothelial cells (HPMEC) and human breast ade-
nocarcinoma cell line (MDA-MB-231) were used for all the siRNA transfection studies.
MDA-MB-231 cells were provided by the Centre for Biological Signalling Studies (BIOSS) and
were genotyped and verified at Labor für DNA Analytik (Freiburg, Germany), while HPMEC
were purchased from ScienCell (Provitro, Germany).
MDA-MB-231 were grown in Dulbecco’s modified Eagle’s Medium (DMEM) (Invitrogen,
Germany) supplemented with 10% FBS (Invitrogen, Germany) and 1% penicillin/streptomycin/
amphotericin B solution (Pan Biotech, Germany) and HPMEC were cultured in Endothelial Cell
Medium (ECM), supplemented with 5% fetal bovine serum (FBS), 1% endothelial cell growth
supplement (ECGS) and 1% penicillin/streptomycin/amphotericin B solution (ScienCell, US/
Provitro, Germany). Cells were cultured in a humidified incubator containing 5% CO2 at 37°C.
TurboGFP expressing MDA-MB-231 and HPMEC were obtained by stable transfection of
TurboGFP using lentiviral transfection and the non-silencing control was obtained using the
pGIPZ vector (Thermo Scientific, Germany). MDA-MB-231 and HPMEC were seeded in 6
well plates at a concentration of 7.0104cells/well and transfected with the lentiviral solution in
complete medium for 24 hours. Puromycin (Sigma-Aldrich, Germany) was added at the con-
centration of 4μg/ml after 48 hours, to select the successfully transfected population.
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Synthesis of polyplexes
The ternary complexes were prepared in DNAse-RNAse free water (GIBCO, Germany).
SiRNA was mixed with branched polyethylenimine (bPEI, 25kDa) at nitrogen/phosphate
group ratio (N/P ratio) of 10 and incubated at room temperature for 20 minutes. bPEI solu-
tion and human serum albumin (HSA, 67 KDa) solution were prepared in DNAse-RNAse
free water and filtered with a 0.22 μm cellulose acetate filter (Corning,NY) immediately prior
to use. The complexation reaction (step) was performed with a fixed siRNA concentration of
22 μg/ml BLOCK-iT Alexa Fluor 555 control siRNA (~13.8 kDa) or 26 μg/ml of Stealth RNAi
TurboGFP siRNA sequence (~16.5 kDa). HSA was added at a final concentration of 0,125
mg/ml and the system was allowed to react for a further 30 minutes. Lipofectamine2000
(Invitrogen, Germany) was used as a positive control, for the uptake and silencing experi-
ments. The lipoplexes were prepared with the same siRNA concentration used for HSA-
bPEI-siRNA ternary complexes and bPEI-siRNA polyplexes, following the protocol guide
from Invitrogen, in relation to the surface area and in relation to cell density (2.8 μl).
Gel Retardation assay and RNAse protection assay
Gel retardation assay and RNAse protection assay were performed loading 10 μl aliquot of the
sample, together with 2μl of loading buffer (Invitrogen, Germany) on a 4% agarose gel, pre-
pared in 1X Tris-boric acid-EDTA (TBE) buffer. Protection against RNase was assessed by in-
cubating the samples for 30 minutes with 17μg/ml of RNAse solution (Sigma-Aldrich,
Germany) followed by gel electrophoresis. The Electrophoresis was carried out in TBE buffer
at 100V for 1 hour. Gel bands were stained with Gel red nucleic acid stain (Biotium, US) for 30
minutes and visualized under UV Fusion FX7 (PeqLab). A 100bp and 10bp DNA ladder (Invi-
trogen, Germany) was included in every run to confirm siRNA integrity.
Determination of Size and Zeta Potential
The mean size of the ternary complex, polydispersity, zeta potential, and stability, were mea-
sured by dynamic light scattering (DLS), using a DelsaNano C particle analyzer (Beckman
Coulter). The complexes were diluted 1:3 with distilled DNAse-RNAse free water for measure-
ment. The stability of the ternary complexes was determined by size measurement at the time-
point of 30 minutes, 1 hour, 2 hours and 4 hours. Morphology and size of the complexes were
further characterized by transmission electron microscopy (TEM) (Zeiss LEO 912 Omega
TEM) at an accelerating voltage of 120 kV. The prepared samples was settled on a CF-400-Cu
square mesh copper grid (Electron Miscroscopy Sciences, USA) and stained with 2% uranil ac-
etate solution. ImageJ software was used to create a statistic of the size of the complexes.
Microscopy of transfection studies
Cell microscopy studies were performed in 8-well chambers (Sarstedt, Germany). 1.5104 cells
were seeded 24 hours before the experiment in 300 μl of complete medium. Alexa Fluor 555
siRNA-labeled complexes were incubated at 37°C for 4 hours. The cells were washed 3 times
with Phosphate Buffered Saline PBS (GIBCO, Germany) and then were fixed in 4% formalde-
hyde solution and stained with DAPI using Vectashield Mounting Medium (Vector Laborato-
ries, Burlingame). Images were acquired in multichannel acquisition mode with Axio Observer
Z1 (Zeiss), with a 20 X objective and the images were processed using Axio vision software.
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Quantification of transfection studies using fluorescence activated cell
sorting (FACS)
Quantitative siRNA internalization in cells was studied measuring the mean fluorescence value
for cell, following the uptake of siRNA-labeled complexes in MDA-MB-231 and HPMEC.
Cells were seeded in 24-well plate at a concentration of 1.0105 in 500 μl of complete medium,
24 hours before the experiment. Cells were then transfected with the complexes for 4 hours in
500μl of serum free medium. Subsequently, cells were washed with PBS and detached with
trypsin from each well. Complete medium with 10% FBS was used to block trypsin action. The
cells were centrifuged at 800 rpm 5 minutes and the pellet was resuspended in PBS 2% FBS.
The fluorescent signal was detected with FACS Gallios (Beckman Coulter) with FL2 channel
(excitation laser: 488 nm; emission filter: 575 nm) and the data were analyzed with Flowing
software 2 (Perttu Terho). Histograms were generated using FlowJo software.
Silencing experiments
Silencing experiments were conducted with MDA-MB-231 and HPMEC expressing TurboGFP.
Cells were seeded in 24-well plate at a concentration of 2.0104 in in 500 μl of complete medium,
24 hours before the experiment. Cells were transfected with the complexes for 4 hours in 500μl of
serum free medium. The medium was replaced with complete medium, containing FBS, for 72
hours. Cells were then washed with PBS and detached with trypsin from each well. Complete me-
dium with 10% FBS was used to block trypsin action. The cells were centrifuged at 800 rpm 5
minutes and the pellet was resuspended in PBS 2% FBS. The fluorescent signal was detected with
FACS Gallios (Beckman Coulter) with FL1 channel (excitation laser: 488 nm; emission filter
525 nm) and the data were analyzed with Flowing software 2 (Perttu Terho). Lypofectamine2000
(Invitrogen) was used as a positive control. Histograms were generated using FlowJo software.
Cell Viability Assay
To test the cytotoxicity of the different formulations, an 3-(4,5-Dimethylthiazol-2yl)2,5-diphe-
nyl-2H-tetrazoliumbromide (MTT) assay (Sigma, Germany) was executed after the incubation
with the complexes. Cells were seeded in a 24-well plate at a concentration of 2.0104 in in
500 μl of complete medium, 24 hours prior to the experiment. The cells were transfected with
the complexes for 4 hours in serum free medium. Then the serum free medium was replaced
with complete medium for 72 hours, testing the cell viability at the same time point of the
knockdown efficiency. Cells were then washed with PBS and 200 μl of a solution of MTT
(0.25 mg/ml in RPMI without phenol red) was added and incubated for 3 h at 37°C. The MTT
solution was removed, 200 μl of DMSO were added to each well and the absorbance at 550 nm
was measured using a Synergy HT plate reader (BioTek).
Uptake mechanism studies
Colocalization studies with selective markers of endocytosis were conducted in both cell lines.
Alexa-Fluor 647 labeled transferrin (Tf) (50μg/ml) and Cholera toxin b (CTB) (3.5μg/ml)
(Invitrogen, Germany) were used as intracellular markers of clathrin-mediated endocytosis
and caveolae-mediated endocytosis. Cells were transfected with Alexa-Fluor 555 siRNA-la-
beled complexes for 2 hours and transferrin (Tf) or cholera toxin b (CTB) were subsequently
added for 30 minutes. Inhibition studies were performed with specific inhibitors: Chlorproma-
zine (2μg/ml for MDA-MB-231 and 5μg/ml for HPMEC), Filipin III (5μg/ml) and Nystatin
(20μg/ml). All the inhibitors were purchased from Sigma-Aldrich. Cells were pre-treated
for 20 minutes with each inhibitor, in serum free medium, and then incubated with the
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siRNA-labeled complexes for 2 hours, without removing the inhibitors. Cells were then trypsi-
nized and collected for FACS fluorescence detection, using FL2 channel (excitation laser: 488
nm; emission filter: 575 nm), and the data were analyzed with Flowing software 2 (Perttu Terho).
The chosen concentrations of each inhibitor were previously tested for cell viability with MTT
test (S3).
Statistical analysis
Statistics were carried using the student t-test module in Excel for paired datasets, assuming a
two-tailed distribution and equal variance between data sets (homoscedastic). A p value
of< 0.05 was considered statistically significant.
Results and Discussion
Characterization of HSA-bPEI-siRNA ternary complex
Due to the negatively charged backbone, delivery of siRNA to cells requires it to be packaged as a
complex with a polycation. Typically, PEI (linear or branched) is the polycation of choice. This
complexation is important to ensure the stability of the siRNA through RNAses and to promote
the entry of siRNA into cells. The polyplexes were formed using branched polyethylenimine
(bPEI) and HSA was introduced as an aqueous solution at pH 7, where it is negatively charged,
thereby capable of interacting with the positive charged amino groups of bPEI (Fig 1A). To arrive
at the chosen ratio between HSA, bPEI and siRNA, we took into consideration a recent study
showed that the ability of bPEI-siRNA at N/P ratio 20 to mediate efficient gene silencing was
higher in comparison to N/P ratio of 5 and 10 [23]. Therefore, with the aim to increase bPEI-
siRNA activity at lower N/P ratio, we employed for this study bPEI at N/P ratio of 10 as this re-
sulted in a good condensation of the siRNA and internalization by cells. The concentration of
HSA that yielded the most measurable change in the size of the polyplexes and an increase in the
cell uptake efficiency was identified using serial dilution as the optimal concentration for the ter-
nary polyplex formation. In general the introduction of HSA to bPEI-siRNA polyplexes resulted
in a dramatic increase in the size, which was also confirmed by TEM (Fig 1B), and in the reversal
of the overall charge of the complexes to a negative value as determined by DLS measurements
(Table 1). This increase in size could be due to either aggregation of smaller polyplexes or reorga-
nization of the bPEI-siRNA complexes, in presence of albumin, to a more thermodynamically
stable structure. Since the association with albumin resulted in complexes ranging in size from
800–1200 nmwith a room temperature stability of about 4 hours (S1 Fig), all the studies were
performed with freshly prepared complexes. We then ascertained if the addition of albumin
would impact the capacity of siRNA to complex with bPEI. Gel Retardation assay showed com-
plete siRNA incorporation by the complexes (Fig 1C) suggesting that HSA adsorption on nano-
complexes surface did not alter the ability of siRNA to condense. Polyplex formation is known to
confer stability against proteolytic degradation [23], and the ability of HSA-bPEI-siRNA to resist
degradation by extracellular endonucleases was verified by RNAse Protection assay (Fig 1D).
HSA colocalizes with siRNA in cells and increases transfection
efficiency
To investigate the cell uptake efficiency of the developed system and to understand the role of
HSA in mediating siRNA delivery, we performed the transfection studies in metastatic human
breast cancer cells (MDA-MB-231) and human pulmonary microvascular endothelial cells
(HPMEC). These cells were chosen as vasculature is important for tumor survival and lung is
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Fig 1. Characterization of HSA-bPEI-siRNA complexes. A) Schematic representation of the two steps
formulation protocol, where bPEI-siRNA native interaction was preserved and HSA was used for interacting
with the positive charged amino-groups of bPEI. B) Transmission electron microscopy (TEM) images
showing the increase in size upon addition of HSA. C) Gel retardation assay, demonstrating siRNA
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the prominent organ for epithelial tumor metastasis [24–25]. Additionally, endothelial cells
and metastatic breast cancer cells have been shown to actively take up albumin [26–27].
To ascertain the role of HSA in the internalization of siRNA, a colocalization study was un-
dertaken, in MDA-MB-231, with fluorescently labeled siRNA. Fluorescence microscopy re-
vealed that HSA colocalizes with siRNA, therefore, clearly shown that HSA enters the cell
intact as an ensemble and participates in the transcellular uptake of siRNA complexes and
their trafficking in the cytosol (Fig 2).
The quantification of HSA-bPEI-siRNA complex internalization was first evaluated in
MDA-MB-231 and HPMEC and compared with bPEI-siRNA polyplexes, using flow cytometry
(FACS). Alexa dye labeled siRNA formulations were used for the study. To eliminate the interfer-
ence from the transfection medium, uptake studies were conducted in serum free medium. Fluo-
rescence micrographs of transfected cells are shown (Fig 3A). FACS analysis showed that the
ternary complexes were taken up to a significantly greater extent in comparison to bPEI-siRNA
polyplexes. The uptake efficiency was about 11 fold greater, in MDA-MB-231, and about 6 fold
greater, in HPMEC, over bPEI-siRNA control. In contrast to HPMEC, where a single gaussian
distribution was observed, in MDA-MB-231 cancer cells a bimodal distribution was observed,
with about 55% of the population showing higher internalization and the remaining population
having similar uptake efficiency of bPEI-siRNA (Fig 3B). It has been known that size, shape and
presence of ligands on the surface of cell delivery systems influence their uptake efficiency and
their mechanism of internalization [28]. The bimodal distribution of HSA-PEI-siRNAmaybe a
result of the combination of the large size of the ternary complex, heterogeneity in the
MDA-MB-231 population, and effects associated with sedimentation of the polyplexes during
transfection. For instance, caveolin1, part of caveolae-mediated endocytosis, is reported to be
down-regulated during the activation of the cell cycle [29]. However, since HPMEC, a well-de-
fined monodispersed cell population yielded a single transfected population, we suggest a possi-
ble role for differential expression of cell-surface proteins in different phases of the cell cycle in
the internalization of the ternary complex rather than the size of the polyplex. Evidence in sup-
port of this conclusion can be found in a study by Ogris et al., who reported that the conjugation
of PEI with tranferrin (Tf) could enhance gene delivery to tumors, despite the formation of com-
plexes up to micrometer size [30]. In this study, the large HSA-bPEI-siRNA complexes also
showed higher uptake. It is possible that a loose association of smaller polyplexes occur and this
could be the reason for the higher efficiency. Further evidence in support of a clear role for HSA
in transporting or facilitating siRNA internalization, was obtained by carrying out transfection in
presence of serum. We hypothesized that since albumin is the dominant protein in serum, it
would compete for trannporters on the cell surface thus dimninishing HSA-bPEI-siRNA ternary
complexation on the top of the gel. From left, 10 base pair ladder (L10); free siRNA (-); PEI-siRNA (PEI);
HSA-PEI-siRNA (+HSA); 100 base pair ladder (L100). D) RNAse protection assay, indicating efficent siRNA
protection from RNAse degradation. Complexes are unaltered on the top of the gel, while free RNA is
completely degraded. From left, 10 base pair ladder (L10); free siRNA (-); samples incubated with RNAse:
free siRNA (+), PEI-siRNA (PEI) and HSA-PEI-siRNA (+HSA); 100 base pair ladder (L100).
doi:10.1371/journal.pone.0122581.g001
Table 1. Size—zeta potential characterization and polydispersity index value.
Size (nm) TEM Size (nm) DLS PDI ζ-potential (mV)
PEI-siRNA 84 ± 17 103 ± 12 0.2 + 2.4 ± 4
HSA-PEI-siRNA 842 ± 230 959 ± 170 0.2 - 4.5 ± 5
Reported values are an average (n = 12)
doi:10.1371/journal.pone.0122581.t001
Enhanced Gene Silencing Using Albumin-Mediated Delivery of siRNA
PLOSONE | DOI:10.1371/journal.pone.0122581 April 9, 2015 8 / 16
polyplex uptake and trasnfection. Interestingly, the transfection efficiency of the ternary complex
was indeed diminished as postulated in presence of serum (S2 Fig).
HSA increases gene silencing in MDA-MB-231 and HPMEC
To see if the increased uptake efficiency translates into higher availability of free siRNA, a gene
silencing study was undertaken using cell lines expressing TurboGFP. In accordance with the
higher internalization, HSA-bPEI-siRNA showed about 12 and 53 times more silencing than
bPEI-siRNA, in MDA-MB-231 and HPMEC, respectively, and was comparable with Lipofecta-
mine, as seen by the reduced TurboGFP fluorescence in cells transfected with the ternary com-
plex. Similar results were also obtained in HPMEC, indicating that HSA complexation with
bPEI-siRNA presents a general strategy for improving the efficiency in siRNA delivery. The
lack of any appreciable gene silencing using bPEI-siRNA may be attributed to poor siRNA in-
ternalization. In MDA-MB-231, 62 ± 1.4% of the cell population was efficiently silenced with
HSA-bPEI-siRNA complexes, with cell fluorescence reduction of 81 ± 2.4% (Fig 4A). For
HPMEC, 69 ± 2.0% of cells showed efficient knockdown, having fluorescence reduction of
88 ± 3.3% for HSA-bPEI-siRNA (Fig 4B). Lipofectamine2000-siRNA showed similar results, in
terms of effectively silenced population and knockdown efficency. The contribution of differ-
ences in cell viability, in the observed higher transfection efficiency with the ternary system,
can be eliminated, as cells exposed to HSA-bPEI-siRNA and bPEI-siRNA complexes showed
comparable viability in MTT assay (S3 Fig). The positive impact of the incorporation of HSA
with PEI appear consistent with the previous studies involving DNA delivery in endothelial
and epithelial cells [17–18] and with the study of Abbasi et al. where siRNA delivery in tumor
cells was accomplished using PEI-coated HSA nanoparticles [19].
Uptake Mechanism of HSA-bPEI-siRNA complexes
In order to understand which uptake mechanismmediates the higher siRNA delivery efficiency of
HSA-bPEI-siRNA, the involvement of clathrin-mediated endocytosis and caveolae-mediated en-
docytosis was elucidated. The size of the complexes influences their entry in cells and their intra-
cellular trafficking. Previous studies have demonstrated that nanospheres with diameter lower
than 200 nm were preferentially internalized by chlatrin mediated pathway, while particles higher
than 500 nm followed the activation of caveolae or “caveosomes”, derived frommultiple caveolae
assemblies on the cellular surface [31–32]. We investigated the uptake inhibition of siRNA-labeled
complexes in presence of Chlorpromazine (CPZ), a known inhibitor of the clathrin pathway, and
Fig 2. Colocalization of HSA and bPEI-siRNA polyplexes in MDA-MB-231. Fluorescence microscopy
revealed that Alexa-fluor 488 labeled HSA and Alexa-fluor 555 siRNA access in the same intracellular
trafficking. (DAPI nuclear stain, blue; Alexa-fluor 555 siRNA labeled complexes, red; Alexa-fluor 488 labeled
HSA, green). White arrows indicate points of colocalization. Scale bar: 20μm.
doi:10.1371/journal.pone.0122581.g002
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Fig 3. Uptake of HSA-bPEI-siRNA and PEI-siRNA complexes in MDA-MB-231 and HPMEC. A)
Representative fluorescence micrographs showing siRNA labeled complexes in cells (DAPI nuclear stain,
blue; Alexa-fluor 555 siRNA labeled complexes, red) Scale bar: 20μm. B) FACS quantitative measurements,
expressed as mean fluorescence value for cell,reveald increased uptake by HSA-bPEI-siRNA complexes,
compared to bPEI-siRNA control, in both cell lines. Results are shown as mean ± SD (n = 3). MDA-MB-231
p<0.001, HPMEC p<0.005.
doi:10.1371/journal.pone.0122581.g003
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Nystatin (Nyst) and Filipin III (Fil III), both cholesterol depletors, that block the formation of
caveolae.The inhibitors concentrations were chosen so as to have minimal impact on cell viability
(S4 Fig). We observed that the ternary complexes are primarily taken up by the caveolae uptake
mechanism in both cells, which this uptake pathway was more pronunced in MDA-MB-231. The
uptake through clathrin mediated endocytosis was around 30% inMDA-MB-231 and HPMEC
(Fig 5A and 5B). Colocalization with cholera toxin b (CTB) in fluorescence microscopy further
confirmed the intracellular trafficking through caveolae (Fig 5C and 5D).
It is well known that endothelial cells have high expression of caveolae [33]. Also multidrug
resistant (MDR) cancer cells have been shown to significantly overexpress caveolae [34]. Since
we have shown that the particles appear to be taken up through caveolae mediated endocytosis,
the higher efficiency could be due to the fact that this pathway is able to bypass lysosomal deg-
radation [35–31]. With regards to albumin trafficiking into cells, Gp60, a protein that is associ-
ated with caveolae complexes has been shown to aid in the transport of albumin across
Fig 4. Protein knockdown efficiency in cells expressing TurboGFP.Cell fluorescence reduction was
estimated to evaluate the percentage of TurboGFP silencing. Both cell lines showed improved siRNA
efficiency compared to bPEI-siRNA control. A) MDA-MB-231 ***p<0.0005. B) HPMEC ***p<0.0005. The
silencing efficiency resulted comparable with Lipofectamine2000-siRNA lipoplexes (LFA-siRNA). Results are
shown as mean ± SD (n = 6).
doi:10.1371/journal.pone.0122581.g004
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Fig 5. Uptake mechanism of HSA-bPEI-siRNA complexes in MDA-MB-231 and HPMEC. The uptake
inhibition was quantified in presence of Nystatin (Nyst), Filipin III (Fil III) and Chlorpromazine (CPZ).
Fluorescence reduction was evaluated in FACS. A) MDA-MB-231; B) HPMEC. Results are shown as
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endothelial and epithelial barriers [36–27]. Therefore, the specific role of gp60 in enhancing
the uptake efficiency of the ternary complex needs to be investigated further.
To further elaborate the role of albumin in the uptake of HSA-bPEI-siRNA complexes, we
substituted HSA with bovine serum albumin (BSA) and we made an interesting observation,
that the uptake efficiency was diminished by over 2 fold in both cell lines. Although HSA and
BSA yielded complexes comparable in size, they showed different uptake profiles (Fig 6) and
mean ± SD (n = 3). From the study, partial involvement of clathrin-mediated pathway was observed, with
around 30% inhibition by CPZ, and low colocalization with Tf. Predominant activation of caveolae-mediated
endocytosis resulted in the internalization of HSA-bPEI-siRNA complexes, in both cell lines. Colocalization
study in fluorescence microscopy with uptake markers cholera toxin b (CTB), marker of caveolae-mediated
pathway, and transferrin (Tf), marker of clathrin-mediated pathway, is shown in C) MDA-MB-231 cells; D)
Colocalization results in HPMEC. White arrows indicate points of colocalization. Scale bar: 20μm.
doi:10.1371/journal.pone.0122581.g005
Fig 6. Uptake efficiency comparing complexes formed with BSA and HSA.Uptake efficiency was
evaluated by FACS. (A) Study in MDA-MB-231, p<0.005; B) Study in HPMEC, p<0.01. Results are shown as
mean ± SD (n = 3). Complexes formed with BSA showed reduced internalization compared with HSA,
confirming the role of HSA in improving siRNA delivery in both cell lines.
doi:10.1371/journal.pone.0122581.g006
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this clearly shows that human albumin confers specificity in the uptake in human cells. Similar-
ly, it has been postulated that the higher efficiency observed when paclitaxel is covalently linked
to HSA (Abraxane) is due to the active uptake of albumin, through the gp60 receptor [26].
Conclusions
In this study, we evaluated the role of native HSA in mediating the uptake and silencing of
siRNA, towards cells expressing TurboGFP. It was observed that the presence of albumin on
the exterior of the bPEI-siRNA polyplexes dramatically improve uptake and gene silencing in
both human endothelial and tumor epithelial cells. Inhibition studies suggest a role for caveolae
mediated endocytosis in the uptake of the ternary complexes. This system offers significant
promise for the in vitro delivery of siRNA.
Supporting Information
S1 Fig. HSA-bPEI-siRNA stability. Ternary complexes stability was evaluated by size mea-
surements by DLS. The study was performed at different time-points: 30 minutes, 1 hour, 2
hours and 4 hours. At the time of 6 hours the complexes were not more detectable, showing
stability for up to 4 hours. Results are shown as mean ± SD (n = 3).
(TIF)
S2 Fig. Cell uptake study comparing HSA-bPEI-siRNA and bPEI-siRNA tranfection in me-
dium with and without fetal bovine serum (FBS). The uptake of the ternary complexes re-
sulted significantly inhibited by serum in A) MDA-MB-231 p<0.0005; B) HPMEC
p<0.005. Results are shown as mean ± SD (n = 3). As control, bPEI-siRNA uptake efficiency
in presence of FBS was also tested, without observing a statistically significant reduction.
(TIF)
S3 Fig. MTT test showing cell viability after transfection. Study performed at the time-point
of 72 hours, after transfection with HSA-bPEI-siRNA, bPEI-siRNA and LFA-siRNA complexes
in A) MDA-MB-231; B) HPMEC. The percentage of cell viability was normalized with untreat-
ed cells. Results are shown as mean ± SD (n = 3). No contribution in cell viability was given to
bPEI-siRNA by the ternary complex, but increased cell viability was observed in comparison
with LFA-siRNA lipoplexes (p<0.0005 in MDA-MB-231 and p<0.005 in HPMEC), con-
sidering the similar protein silencing efficiency.
(TIF)
S4 Fig. MTT test showing cell viability after incubation with inhibitors, at the concentra-
tion used. Cell viability in A) MDA-MB-231; B) HPMEC. Results are shown as mean ± SD
(n = 3). Cell viability resulted in both cell lines between 80 and 90% in comparison with
untreated cells.
(TIF)
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